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Background. A high proportion of COVID-19 patients
have cardiac involvement, even those without
known cardiac disease. Downregulation of angio-
tensin converting enzyme 2 (ACE2), a receptor for
SARS-CoV-2 and the renin-angiotensin system, as
well as inflammatory mechanisms have been sug-
gested to play a role. ACE2 is abundant in the gut
and associated with gut microbiota composition.
We hypothesized that gut leakage of microbial
products, and subsequent inflammasome activa-
tion could contribute to cardiac involvement in
COVID-19 patients.
Methods. Plasma levels of a gut leakage marker (LPS-
binding protein, LBP), a marker of enterocyte
damage (intestinal fatty acid binding protein,
IFABP), a gut homing marker (CCL25, ligand for
chemokine receptor CCR9) and markers of inflam-
masome activation (IL-1b, IL-18 and their regula-
tory proteins) were measured at three time points
(day 1, 3–5 and 7–10) in 39 hospitalized COVID-19
patients and related to cardiac involvement.
Results. Compared to controls, COVID-19 patients
had elevated plasma levels of LBP and CCL25 but
not IFABP, suggesting impaired gut barrier func-
tion and accentuated gut homing of T cells without
excessive enterocyte damage. Levels of LBP were
twice as high at baseline in patients with elevated
cardiac markers compared with those without and
remained elevated during hospitalization. Also,
markers of inflammasome activation were moder-
ately elevated in patients with cardiac involvement.
LBP was associated with higher NT-pro-BNP levels,
whereas IL-18, IL-18BP and IL-1Ra were associ-
ated with higher troponin levels.
Conclusion. Patients with cardiac involvement had
elevated markers of gut leakage and inflammasome
activation, suggestive of a potential gut-heart axis
in COVID-19.
Keywords: CCR9, COVID-19, gut, heart, inflamma-
some, LBP.
Introduction
A substantial proportion of hospitalized COVID-19
patients have cardiac involvement [1, 2]. Previous
cardiovascular disease (CVD) and risk factors for
CVD such as obesity seem to be major risk factors
for developing severe COVID-19 [1–4]. However, a
high proportion of COVID-19 patients have cardiac
involvement without previous CVD [2]. Cardiac
involvement has also emerged as a significant and
life-threatening complication in COVID-19
patients, ranging from myocardial infarction (MI)
and myocarditis to pulmonary hypertension with
cardiac stress [5–9].
The mechanisms underlying this cardiac involve-
ment are not clear. Downregulation of the anti-
inflammatory and cardioprotective angiotensin
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(AT)-1-7 pathway secondary to downregulation of
angiotensin converting enzyme ACE2, the SARS-
CoV-2 receptor, direct infection of the myocardium
through ACE2 expressing cardiac cells and hyper-
inflammation have been suggested to be of impor-
tance [10–13]. ACE2 is ubiquitously expressed in
several organs, and in addition to pulmonary,
cardiac and renal tissues, ACE2 is also expressed
in the gut, where ACE2 expression in enterocytes
may serve as sites for SARS-CoV-2 entrance and
predispose to enteric infection [14].
Data suggest that severe SARS-CoV-2 infection
could lead to degeneration of the gut-blood barrier
leading to systemic spread of bacteria and leakage
of microbial products, possibly affecting the host’s
response to COVID-19 infection and contribute to
disease severity [15–20]. A large GWAS study
identified mutations in the chemokine receptor
CCR9 as a major risk factor for developing severe
COVID-19 [21]. CCR9 is differentially expressed on
T cells and regulate homing of T cells to the mucosa
of the small intestines and the colon via interaction
with the CCR9 ligand CCL25 [22, 23]. This under-
scores a potential role of gut mucosal function and
inflammation in the pathogenesis of COVID-19-
related disease.
An accumulating amount of evidence has shown
that the gut microbiota composition and the gut-
blood barrier are altered in various forms of CVD
[24]. Nod-like Receptor Protein (NLRP) 3 inflamma-
some activation seems to play a major role in the
pathogenesis of CVD, mainly through enhanced
release of the inflammatory cytokines interleukin
(IL)-1b and IL-18 [25, 26]. NLRP3 inflammasome
activation has also been suggested as an important
link between altered gut microbiota composition,
impaired gut barrier and systemic inflammation
[27], partly through priming of NLRP3 inflamma-
some through interaction between lipopolysaccha-
ride (LPS) and toll-like receptor (TLR)4 [28]. The
NLRP3 inflammasome has also been proposed to
play a role in the pathogenesis COVID-19, but data
on the role of these inflammasomes in the gut-
heart axis in COVID-19 patients are scarce or
lacking [29].
Herein, we measured plasma levels of LPS-binding
protein (LBP) and intestinal fatty acid binding
protein (IFABP) as markers of disturbed gut barrier
[30], CCL25 as a marker of T cell homing in the gut,
and IL-1 and IL-18 as well as their regulatory
proteins as the major products of NLRP3
inflammasome activation. We hypothesized that
gut leakage mechanisms involving LPS- and
CCL25-driven intestinal inflammation through
NLRP3 activation could contribute to cardiac




Hospitalized adult patients (≥18 years old) with
confirmed positive SARS-CoV-2 PCR test targeting
the E-gene on oro- or nasopharyngeal specimens,
were consecutively recruited from Oslo University
Hospital Ulleval and Drammen Hospital, Vestre
Viken Hospital Trust between March 6 and April 14
to a clinical cohort study (Norwegian SARS-CoV-2
study; ClinicalTrials.gov number NCT04381819).
Clinical information and laboratory samples were
collected at the earliest time point after hospital-
ization. Peripheral blood was collected at day of
inclusion (within 48 h of admission), day 3–5 and
day 7–10 after hospitalization. Using a modified
version of the International Severe Acute Respira-
tory and emerging Infection Consortium (ISARIC)/
World Health Organization Clinical Characteriza-
tion Protocol, clinical and routine data were
abstracted from electronic medical records into
the ISARIC (isaric.tghn.org) REDCap database
(Research Electronic Data Capture, Vanderbilt
University, USA, hosted by University of Oxford,
UK).
For reference, the actual markers were also anal-
ysed in plasma from 16 healthy controls recruited
at the Research Institute of Internal Medicine,
OUH, based on disease history and normal labo-
ratory tests (Table 1).
Ethical considerations
Informed consents were obtained from all partici-
pants. The study was approved by the South-
Eastern Norway Regional Health Authority (refer-
ence number: 106624).
Study outcome definitions
The main outcome was cardiovascular (CV) end-
point defined by cardiac markers above reference
values at any time during hospitalization: N-termi-
nal pro-B-type natriuretic peptide (NT-proBNP)
reflecting cardiac wall stress (women: <50 years
(y) 170–299 ng L1; 50–69 y 300–759 ng L1; ≥70
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y ≥ 760 ng L1, men: <50 y 85–249 ng L1; 50–69
y 250–499 ng L1; ≥70 y ≥ 500 ng L1) and/or
cardiac troponins reflecting myocardial damage:
troponin T (TnT) (≥14 ng mL1), or TnI
(women ≥ 15 ng mL1, men ≥ 30 ng mL1). Cut-
off references as provided by local laboratories
based on product information from Roche (NT-
proBNP and TnT) and Abbot (TnI).
Sample processing
Peripheral blood was collected into 4 mL Vacuette
(Greiner bio-one International) with EDTA as anti-
coagulant. Samples were immediately stored on
ice, and within 30 min plasma was isolated by
centrifugation at 2000 g for 20 min at 4°C to
obtain platelet poor plasma. Plasma were immedi-
ately stored at 80°C in aliquots until analysis.
Markers of gut leakage and inflammasome activation
Plasma levels of IFABP, CCL25, IL-18, IL-18 bind-
ing protein (IL-18BP) and LBP were measured in
duplicate by enzyme immunoassays (EIA) using
commercially available antibodies (R&D Systems,
Minneapolis, MN, USA) in a 384 format using a
Table 1. Baseline characteristics of COVID-19 patients and controls
Controls All patients Cardiac involvement
(n = 16) (n = 39) No (n = 17) Yes (n = 22)
Women, n (%) 7 (44) 10 (26) 6 (35) 4 (18)
Age, years 66  7 61  15 58  13 63  16
Time from symptoms, days – 9.6  3.7 9.7  4.2 9.6  3.2
Caucasian, n (%) 16 (100) 27 (69) 10 (59) 17 (77)
Current smoker, n (%) 3 (19) 8 (21) 1 (6) 7 (32)
P/F ratio 42.4  15.3 47.0  17.1 37.6  12.2
Comorbidities
Cardiovascular, n (%) 0 (0) 9 (23) 2 (12) 7 (32)
Pulmonary, n (%) 0 (0) 1 (2.6) 0 (0) 1 (4.5)
Asthma, n (%) 0 (0) 8 (21) 4 (24) 4 (18)
Renal, n (%) 0 (0) 4 (10) 0 (0) 4 (18)
Liver, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Neurological, n (%) 0 (0) 1 (3) 0 (0) 1 (5)
Cancer, n (%) 0 (0) 1 (3) 1 (6) 0 (0)
Hematological, n (%) 0 (0) 1 (3) 1 (6) 0 (0)
Obesity, n (%) 0 (0) 5 (13) 2 (12) 3 (14)
Diabetes, n (%) 0 (0) 3 (8) 1 (6) 2 (9)
Rheumatic, n (%) 0 (0) 4 (10) 1 (5) 3 (14)
Biochemistry
Haemoglobin, g/dL 14.5  0.9 13.3  1.7** 12.7  1.6 13.7  1.7
Leucocytes, 9109 L1 5.6  1.2 6.6  3.2 5.3  2.0 7.7  3.6*
Lymphocytes, 9109 L1 1.7  0.7 1.1  0.5** 1.2  0.5 1.0  0.4
Monocytes, 9109 L1 0.5  0.2 0.4  0.2 0.5  0.2 0.4  0.2
Neutrophils, 9109 L1 3.2  0.7 5.1  3.2* 3.5  1.9 6.3  3.6*
Platelets, 9109 L1 254  70 202  59** 212  52* 194  66
CRP mg/L 1.6 [0.8, 4] 59 [31, 132]*** 31 [15, 75] 109 [47, 179]**
ALT, U L1 29  13 43  41 58  55 32  19
AST, U L1 32  9 49  38 58  47 36  10
Continuous data are given as mean  standard deviation. *P < 0.05, **P < 0.01 versus controls or COVID-19 patients
without cardiac involvement, respectively.
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combination of a SELMA (Jena, Germany) pipetting
robot and a BioTek (Winooski, VT, USA) dispenser/
washer. Absorption was read at 450 nm with
wavelength correction set to 540 nm using an EIA
plate reader (Bio-Rad, Hercules, CA, USA). Plasma
levels of IL-1b and IL-1Receptor antagonist (IL-1Ra)
were analysed using a multiplex cytokine assay
(Bio-Plex Human Cytokine 27-Plex Panel; Bio-Rad
Laboratories Inc., Hercules, CA, USA). The samples
were analysed on a Multiplex Analyzer (Bio-Rad
Laboratories) according to the manufacturer’s
instructions.
Statistical analysis
Patient characteristics were compared using Stu-
dent’s t-test and Mann–Whitney U test or chi-
square for continuous and categorical variables,
respectively (Table 1). The temporal profiles of
IFABP, CCL25, LBP, IL-18, IL18BP and IL-1Ra,
were analysed by a generalized linear mixed model.
Markers were categorized as day 1 (i.e. within 48 h
of admission), day 3–5 and day 7–10 giving three
time categories (Figure 1) and were log trans-
formed. Marker was used as dependent, outcome
measure and time as fixed factors, and patient
number as random factor.
We further used linear mixed models to model the
association between inflammasome markers (out-
come) and gut-related biomarkers included indi-
vidually in separate models, with time treated as a
factor variable. A random intercept by subject was
used to control for repeated measures, with each
subject having between 1 and 3 measured follow-
up periods. Skewed data were log transformed and
standardized.
Correlation analyses between markers of gut leak-
age and inflammasome activation were performed
at individual time points (Spearman). The predic-
tive value of LBP and inflammasome markers for
troponin and NT-proBNP levels was examined by
logistic regression. LBP and inflammasome mark-
ers were log transformed and normalized, and
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Fig. 1 Circulating levels of gut and inflammasome markers in relation to cardiac involvement. Temporal course of gut-
related (upper panel) and inflammasome related (lower panel) markers during COVID-19 infection according to cardiac
involvement. Data are presented as back-transformed estimated marginal means with 95% confidence intervals from the
general linear model procedure (see Statistical methods) and the P-value for the group effect according to cardiac
involvement is given on the graphs. The grey area represents the estimated marginal mean (line) and 95% confidence
interval (grey area) of healthy controls (n = 16).
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according to gender and age-related cut-offs. P-
values are two-sided and considered significant
when <0.05. SPSS release 26.0.0.1 (IBM, Chicago,
Illinois, USA) was used for statistical analysis.
Results
Demographics
Table 1 shows demographics and clinical charac-
teristics of the 39 COVID-19 patients and 16
healthy controls. COVID-19 patients had a mean
age of 61 years, 74% were men, 21% were current
smokers, and 23% had previous CVD. Controls
were slightly older with a mean age of 66 years,
56% were men, and 19% were current smokers. In
COVID-19 patients, the mean time from onset of
symptoms to admission was 9.6 days.
In total, 56% of patients had elevated levels of
cardiac markers above gender and age-related cut-
offs as defined in Methods. No significant differ-
ences in age, time from symptoms to admission or
major comorbidities including previous CVD were
detected in relation to cardiac involvement.
Numerically a larger proportion of patients with
cardiac involvement were current smokers, but the
difference was not significant.
COVID-19 patients have elevated levels of LBP, CCL25 and markers of
inflammasome activation
As shown in Figure 1, COVID-19 patients had
elevated plasma levels of LBP compared to controls
at baseline (P < 0.001), suggesting impaired gut
barrier function and endotoxin activity, while
plasma levels of IFABP, a marker of enterocyte
damage, were not elevated in COVID-19 patients.
Also plasma levels of CCL25 were elevated in
COVID-19 patients (P < 0.001), suggestive of a
higher potential for influx of gut homing of T cells
to the chemokine receptor CCR9. However, we
found no correlation between lymphocyte count
and CCL25 levels. Plasma levels of IL-18
(P < 0.001) and IL-18BP (P < 0.01), were also ele-
vated in COVID-19 patients compared to controls
at baseline, suggesting increased inflammasome
activation (Fig. 1). Plasma levels of IL-1b and IL-
1Ra from COVID-19 patients were measured by a
multiplex cytokine assay, and not analysed in the
controls. However, the levels were higher in
COVID-19 patients than that found in a healthy
control group previously published by Hennø et al.
[31] as reported for this COVID-19 cohort
(submitted paper). Time from symptoms´ onset
did not differ between those with and without
cardiac involvement and did not correlate with the
analysed biomarkers or levels of NT-proBNP or
troponin.
LPS-driven inflammation and inflammasome activity in relation to
cardiac involvement in COVID-19 patients
When comparing COVID-19 patients with elevated
cardiac markers to those without, LBP levels were
twice as high at day 1 in patients with cardiac
involvement and remained higher at three time
points during the hospital stay (Fig. 1). In contrast,
CCL25 and IFABP, also related to gut inflammation
and leakage, were not associated with cardiac
involvement. Among markers of inflammasome
activity, IL-18 and IL-18BP, but not IL-1b and IL-
Ra were elevated throughout the hospital stay in
patients with cardiac involvement (Fig. 1).
A large proportion of the COVID-19 patients had
previous history of CVD, but among patients with
elevated cardiac markers, only IL-18BP levels were
elevated in patients with previous CVD as com-
pared with those without (P = 0.045), whereas
levels IL-18 and LBP were not. There were no
significant differences between smokers and non-
smokers in levels of LBP, IL-18 and IL-18BP.
Furthermore, there was no difference in respiratory
failure as measured by PaO2/FiO2 ratio between
those with and without cardiac involvement
(Table 1).
Finally, patients with cardiac involvement had
higher levels of CRP, neutrophil counts and neu-
trophil:lymphocyte ratio. CRP levels correlated
with LBP (rho = 0.63, P < 0.001), but not with
markers of inflammasome activation.
Markers of inflammasome activation are related to troponin levels and
LBP to NT-pro-BNP
Correlations between biomarkers at baseline are
presented as a correlation matrix in Fig. 2, reveal-
ing positive correlations between IL-18BP and LBP.
To further investigate potential associations over
time, we applied mixed models with markers of
inflammasome activation as dependent variables
and LBP and time as covariates. As shown in
Table 2, LBP was significantly associated over time
with IL-18 and IL-1Ra, supporting our overall
hypothesis of LPS-driven priming of the NLRP3
inflammasome.
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As markers of inflammasome activation and gut
barrier impairment could be related to different
aspects of cardiac involvement, we analysed these
markers in relation to elevated levels of troponin
and NT-pro-BNP in logistic regression analyses.
Whereas IL-18, IL-18BP and IL-1Ra all associated
with elevated troponin levels, but not with NT-pro-
BNP, the opposite pattern was observed for LBP,
which associated with elevated NT-pro-BNP but
not with troponin levels (Table 3). Of note, LBP was
not correlated with respiratory failure (PaO2/FiO2
ratio), suggesting that the association to NT-pro-
BNP is not exclusively driven by increased pul-
monary affection.
Discussion
In the present study, we hypothesized that gut
leakage of microbial products, and subsequent
inflammasome activation could contribute to car-
diac involvement in COVID-19 patients. Our find-
ings can be summarized as follows: (i) Compared to
controls, COVID-19 patients had elevated plasma



























































































Fig. 2 Correlation matrix at baseline. Correlation matrix at baseline with rho values and *P < 0.05, **P < 0.01,
***P> 0.001.
Table 2. Association between markers of gut involvement and inflammasome activation over time
IL-18 IL-18BP IL-1b IL-1Ra
LBP 0.29** (0.11, 0.47) 0.18 (0.07, 0.42) 0.04 (0.37, 0.29) 0.34* (0.02, 0.66)
CCL25 0.01 (0.10, 0.12) 0.08 (0.30, 0.13) 0.06 (0.20, 0.31) 0.27* (0.03, 0.52)
IFABP 0.07 (0.17, 0.02) 0.02 (0.19, 0.23) 0.01 (0.24, 0.24) 0.13 (0.11, 0.37)
Linear mixed model with markers of inflammasome activation as dependent, time as fixed effect, and biomarker as
covariates (LBP, CCL25 or IFABP), and subject as random effect. Data are given as parameter estimates (95%CI) and
*P < 0.05,
**P < 0.01.
Significant values are in bold.
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barrier function and accentuated gut homing of T
cells, (ii) baseline levels of LBP were twice as high in
patients with cardiac involvement compared to
those without and remained elevated during the
hospital stay, (iii) IL-18 and IL-1Ra correlated with
LBP over time and were significantly elevated in
patients with current cardiac involvement and (iv)
whereas inflammasome markers (IL-18, IL-18BP
and IL-1Ra) were associated with elevated troponin
levels, LBP associated with elevated NT-pro-BNP.
Several studies, including work from our own
group, have over the last years consistently
reported gut microbiota alterations in cohorts of
heart failure and coronary artery disease, with
common findings being reduction in microbes with
capacity for producing butyrate, which is vital for
the gut mucosal function [24]. A dysfunctional gut
mucosal barrier will facilitate passive leakage of
microbial products, such as LPS to the circulation,
which again could contribute to systemic inflam-
mation at least partly through inflammasome acti-
vation. Moreover, in line with the present study, we
recently reported that increased plasma levels of
LBP predicted cardiovascular events in a high-risk
population of elderly men [32].
Gut impairment could trigger inflammation in
several ways, among others by LPS-priming of the
NLRP3 inflammasome, which has been shown to
play a central role in CVD [33–35] as well as in the
pathogenesis of COVID-19 [36]. Furthermore, the
chemokine receptor CCR9 that is expressed by the
intestinal epithelial cells, was recently identified in
a large GWAS study as a potential risk factor for
developing severe COVID-19 diseases [21], under-
scoring a potential role of the gut in the pathogen-
esis of COVID-19-related disease. Of note, levels of
LBP and the CCR9 ligand CCL25 were elevated in
COVID-19 patients, and it is tempting to hypoth-
esize that LPS and CCL25 could contribute to gut
mucosal impairment through promoting intestinal
inflammation [37]. As COVID-19 patients are often
characterized by lymphopenia, we also hypothe-
sized that this could partly be explained by gut
homing of lymphocytes. However, we found no
association between CCL25 levels and lymphocyte
count.
Whereas levels of IL-18 and its binding protein
were associated with cardiac involvement in
COVID-19 patients, this was not seen for the other
major inflammatory NLRP3 inflammasome pro-
duct, IL-1b. Nevertheless, in addition to IL-18 and
IL-18BP, also IL-1Ra associated with elevated
troponin levels. The reason for this pattern is at
present not clear but could be related to method-
ological issues. It is well known that an accurate
measurement of IL-1b in circulation could be
difficult, and we cannot exclude that IL-1b could
be of importance for cardiac involvement in the
microenvironment.
We recently reported that elevated circulating
markers of inflammasome activation, including
IL-1Ra but not IL-1b predicted first-time MI in
HIV [38], another viral infection where inflamma-
some activation is probably involved in disease
pathogenesis through pyroptosis [39]. Strategies to
inhibit IL-1 activation by the monoclonal antibody
canakinumab was recently shown to reduce the
risk of re-infarction in the CANTOS trial [25].
Retrospective cohort studies with IL-1 inhibition
with the short-acting IL-1 receptor antagonist
anakinra in COVID-19 patients have shown
promising results [40] and is now being tested in
several controlled trials, such as the CAN-COVID
study [29, 41–43].
Whereas markers of inflammasome activation were
associated with elevated troponin levels reflecting
myocardial damage, LBP levels associated with NT-
Table 3. Gut leakage and inflammasome activation in association with elevated cardiac markers
LBP IL18 IL18BP IL-1b IL-1Ra
Elevated Troponin 1.23 (0.74, 2.06) 3.57 (1.70, 7.47) 4.68 (1.94, 11.29) 1.53 (0.91, 2.59) 2.03 (1.15, 3.58)
P = 0.431 P = 0.001 P = 0.001 P = 0.111 P = 0.015
Elevated Nt-proBNP 2.62 (1.34, 5.12) 1.40 (0.78, 2.53) 1.47 (0.85, 2.56) 1.23 (0.74, 2.04) 1.42 (0.84, 2.41)
P = 0.005 P = 0.265 P = 0.168 P = 0.428 P = 0.193
Logistic regression analyses with elevated levels of troponin and NT-proBNP as outcome measures, dichotomized
according to gender and age-related cut-offs given in Methods. Data are given as odds ratios (95% CI), with significant
associations in bold.
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pro-BNP, but not with troponin levels. Whether the
remarkably high LBP levels in patients with ele-
vated cardiac markers reflect gut damage with
potential cardiac involvement, or the other way
around with congestion casing intestinal oedema,
cannot be answered in an observational study.
Long-term follow-up with cardiac imaging in com-
bination with microbiota analyses from the gut
compartment would be the necessary next step to
further test the potential impact of the gut-heart
axis in COVID-19 patients.
Our study has several limitations. First, this study
included a small number of patients and the
results should be interpreted as exploratory.
Second, we did not have plasma samples available
for all patients at all time points, although the
chosen statistical model does not require complete
data set. Third, controls were not matched for age
and gender, and comparisons between COVID-19
patients and controls should be interpreted with
caution. Furthermore, the diagnosis of cardiac
involvement is based purely on elevated levels of
cardiac markers as cardiac imaging were not
feasible and does not allow us to separate between
different etiologies of cardiac involvement includ-
ing MI, myocarditis, heart failure or pulmonary
hypertension with cardiac involvement.
In summary, our data show that hospitalized
COVID-19 patients with cardiac involvement were
characterized by elevated markers of gut leakage
and inflammasome activation. In light of our find-
ings, COVID-19 patients with cardiac involvement
could be of particular relevance for intervention
trials targeting inflammasome activation.
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